

Medical Breast Training Program: High-Risk Prevention & Early Detection Online Course

Activity Description

Mayo Clinic and Cleveland Clinic's collaborative Medical Breast Training Program: High-Risk Prevention & Early Detection Online Course prepares clinicians to identify and manage women at increased risk for breast cancer. It covers hereditary and familial risk guidelines, assessment models, high-risk lesions, risk-reduction strategies, surveillance imaging, early detection, and case-based learning.

Target Audience

This course is specifically tailored for specialty groups including medical oncology, women's health, family medicine, and primary care. The content is designed to meet the educational needs of physicians, nurse practitioners, physician assistants, registered nurses, and allied health professionals.

Learning Objectives

Upon conclusion of this activity, participants should be able to:

- Identify patients at increased risk for breast cancer using clinical, familial, and genetic risk factors.
- Apply evidence-based guidelines (e.g., NCCN, JCO) to determine appropriate screening strategies, imaging modalities, and surveillance intervals for high-risk individuals.
- Identify high-risk breast lesions by incorporating current surgical and non-surgical recommendations.
- List risk-reducing strategies tailored to individual risk profiles and comorbidities.
- Recall risk assessment models to guide clinical decision-making for familial and hereditary breast cancer risk.
- Recite survivorship care principles into the management of high-risk patients and breast cancer survivors.
- List the risks, benefits, and limitations of various screening, diagnostic, and preventive strategies.

Attendance at this Mayo Clinic course does not indicate nor guarantee competence or proficiency in the performance of any procedures which may be discussed or taught in this course.

Accreditation Statement



In support of improving patient care, Mayo Clinic College of Medicine and Science is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Statement(s)

AMA

Mayo Clinic College of Medicine and Science designates this enduring material for a maximum of 17.00 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ANCC

Mayo Clinic College of Medicine and Science designates this enduring material for a maximum of 17.00 ANCC contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

AAPA



Mayo Clinic College of Medicine and Science has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. Approval is valid until 4/6/2029. This activity is designated for 17.00 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

ACHE

By attending the Medical Breast Training Program: High-Risk Prevention & Early Detection Online Course offered by Mayo Clinic College of Medicine and Science participants may earn up to 17.00 ACHE Qualifying Education Hours toward initial certification or recertification of the Fellow of the American College of Healthcare Executives (FACHE) designation.

Other Healthcare Professionals

A record of attendance will be provided to all registrants for requesting credits in accordance with state nursing boards, specialty societies or other professional associations.

Disclosure Summary

As a provider accredited by Joint Accreditation for Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science must ensure balance, independence, objectivity and scientific rigor in its educational activities. All who are in a position to control the content are required to disclose all financial relationships with any ineligible company. Faculty will also identify any off-label and/or investigational use of pharmaceuticals or instruments discussed in their content for FDA compliance.

Listed below are individuals with control of the content of this program who have disclosed...

Relevant financial relationship(s) with ineligible companies:

Name	Nature of Relationship	Company
Maria Hurtado Andrade	Honoraria	Novo Nordisk
Juliana Kling	Honoraria	Bayer Pharmaceuticals
Juliana Kling	Honoraria	Paradise Valley Country Club
Mara Piltin	Intellectual Property	Optiscan Imaging Ltd (ASX: OIL)
Mara Piltin	Intellectual Property	TYBR Health, Inc.
Mara Piltin	Presentation CME	Axogen inc
Mara Piltin	Research Grant	Intuitive Surgical
Sandhya Pruthi	Honoraria	Conde-Nast
Sandhya Pruthi	Stock Equity	Abbott
Sandhya Pruthi	Stock Equity	Abbvie
Sandhya Pruthi	Stock Equity	Becton Dickinson
Sandhya Pruthi	Stock Equity	Biontech
Sandhya Pruthi	Stock Equity	Cirsper
Sandhya Pruthi	Stock Equity	Embecta
Sandhya Pruthi	Stock Equity	Illumina
Sandhya Pruthi	Stock Equity	Moderna
Sabrina Sahni	Honoraria	Astellas Pharma US, Inc.
Siddhartha Yadav	Honoraria	AstraZeneca Pharmaceuticals LP
Zahraa Alhilli	Consultant	Abbvie
Mindy Christianson	Consultant	Medical Advisory Board

		EMD Serono
Paulette Turk	Consultant	Merit Medical

All relevant financial relationships listed for these individuals have been mitigated.

No relevant financial relationship(s) with ineligible companies:

Name
Julie Billar
Molly Brownfield Hess
Patricia Cronin
Jessica Fraker
Melanie Frederixon
Laura Harper
Aparna Kaur
Christine Klassen
Sarah Mantia
Sarah McLaughlin, M.D.
Kaitlin Moran
Christine Nguyen
Laura Ongie
Kristin Robinson
DeAnna Weaver
Karen Hurley
Lakshmi Khatri
Ryan Noss
Graham Schwartz
Niconna Willis
Corinne Irish
Michelle Cooper

References to off-label and/or investigational usage(s) of pharmaceuticals or instruments in their presentation:

Name	Manufacturer/Provider	Product/Device/Medication
Jessica Fraker	AstraZeneca/ANI	Anastrozole (Arimidex)
Jessica Fraker	Pfizer	Exemestane (Aromasin)
Juliana Kling	AI as risk reducing medication	Aromatase inhibitors
Mara Piltin	Intuitive Surgical	Robotic Mastectomy
Sandhya Pruthi	Pfizer	Exemestane
Sandhya Pruthi	ANI Pharmaceuticals	Anastrozoe

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) please visit: <https://ce.mayo.edu/content/disclosures>.

Disclaimer

Participation in this Mayo Clinic educational activity does not indicate nor guarantee competence or proficiency in the performance of any procedures which may be discussed or taught in this course. You should be aware that substantive developments in the medical field covered by this recording may have occurred since the date of original release.

Prerequisites for Participation

There are no prerequisites needed prior to participating in this education activity.

Method of Participation

Participation in this activity consists of reviewing the educational material, completing the learner assessment and evaluation.

How to Obtain Credit

To obtain credit, complete the assessment, evaluation and submit.

Release and Expiration Dates

Release Date:	April 7, 2026
Renewal Date:	(If applicable)
Expiration Date:	April 6, 2029

Acknowledgement of Commercial Support

No commercial support was received in the production of this activity.

Faculty and Course Director Listing and Credentials

Course Director(s)

Sandhy Pruthi, M.D.
Sabrina Sahni, M.D.
Jessica Fraker, M.D.
Lakshmi Khatri, M.D. (Cleveland Clinic)
Melanie A. Frederixon, APRN, C.N.P., D.N.P.

Mayo Clinic Faculty

Kristin A. Robinson, M.D.
Aparna S. Kaur, M.D.
Christine L. Klassen, M.D.
Christine Q. Nguyen, D.O.
DeAnna M. Weaver, APRN, C.N.P., M.S.N.
Jessica L. Fraker, M.D.
Jewel M. Kling, M.D., M.P.H.
Julie A. Billar, M.D.
Kaitlin M. Moran, M.D.
Laura Harper, M.D.
Laura J. Ongie, M.S., CGC
Mara A. Piltin, D.O.
Maria Daniela Hurtado Andrade, M.D., Ph.D.
Melanie A. Frederixon, APRN, C.N.P., D.N.P.

Patricia A. Cronin, M.D.
Sabrina Sahni, M.D.
Sandhya Pruthi, M.D.
Sarah A McLaughlin, M.D.
Sarah K. Mantia, M.S., CGC
Siddhartha Yadav, M.B.B.S., M.D.

Cleveland Clinic Faculty

Graham Schwarz, M.D.
Karen Hurley, Ph.D.
Lakshmi Khatri, M.D.
Mariam Alhilli, M.D.
Mindy Christenson, M.D., M.B.A.
Paulette Turk, M.D.
Ryan Noss, M.S., CGC
Zahraa Alhilli, M.D., M.B.A.

Bibliographic Resources

US Preventive Services Task Force. Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2019;322(9):857–867. doi:10.1001/jama.2019.11885

Visvanathan K, Fabian CJ, Bantug E, et al. Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update. *J Clin Oncol*. 2019;37(33):3152-3165. doi:10.1200/JCO.19.01472

Klassen CL, Fraker JL, Pruthi S. Updates on Management of Atypical Hyperplasia of the Breast. *Mayo Clin Proc*. 2025;100(6):1051-1057. doi:10.1016/j.mayocp.2025.01.029

Copyright

Mayo Foundation for Medical Education and Research. All rights reserved. Copyright 2026